Outlook Therapeutics Profit Margin

The latest profit margin for OTLK is -49776.98% as of June 2026. That compares with -8270.57% in the prior-year period — down 501.9% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Outlook Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, OTLK's profit margin moved from -8270.57% to -49776.98% — a 501.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Outlook Therapeutics's valuation or profitability profile.

Against Healthcare companies, OTLK currently prints -49776.98% for profit margin, while the sector average sits near 14.41%. That is roughly 345419.0% below the sector mean. Large gaps often invite a closer look at Outlook Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Outlook Therapeutics converts resources into returns. At -49776.98%, OTLK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8270.57% in the prior-year period — down 501.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OTLK's profit margin (-49776.98%), review year-over-year change from -8270.57%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.